Here we provide the proof-of-concept for an unconventional and effective nanotechnology-based inhalation approach for delivery of a synthetic miRNA mimic via biocompatible and biodegradable calcium phosphate-based nanoparticles (CaPs) preferentially to cardiomyocytes without significant accumulation in other myocardial cells or organs.

Nano-miR-133a Replacement Therapy Blunts Pressure Overload-Induced Heart Failure

Modica J.;Di Mauro V.;Carullo P.;Condorelli G.;Iafisco M.;Miragoli M.;Catalucci D.
2021

Abstract

Here we provide the proof-of-concept for an unconventional and effective nanotechnology-based inhalation approach for delivery of a synthetic miRNA mimic via biocompatible and biodegradable calcium phosphate-based nanoparticles (CaPs) preferentially to cardiomyocytes without significant accumulation in other myocardial cells or organs.
2021
Istituto di Ricerca Genetica e Biomedica - IRGB
Istituto di Scienza, Tecnologia e Sostenibilità per lo Sviluppo dei Materiali Ceramici - ISSMC (ex ISTEC)
cardiomyocytes
heart failure
inhalation
microRNAs
nanoparticles
RNA
therapeutics
File in questo prodotto:
File Dimensione Formato  
2022_Modica et al_ Circulation.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Altro tipo di licenza
Dimensione 376.72 kB
Formato Adobe PDF
376.72 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/446060
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 22
social impact